Sobre el VHIR
Al Vall d’Hebron Institut de Recerca (VHIR) promovem la recerca biomèdica, la innovació i la docència. Més de 1.800 persones busquen comprendre les malalties avui per millorar-ne el tractament demà.
Recerca
Treballem per entendre les malalties, saber com funcionen i crear millors tractaments per als pacients. Coneix els nostres grups i les seves línies de recerca.
Persones
Les persones són el centre del Vall d'Hebron Institut de Recerca (VHIR). Per això ens vinculem amb els principis de llibertat de recerca, igualtat de gènere i actitud professional que promou l’HRS4R.
Assaigs clínics
La nostra tasca no és només bàsica o translacional; som líders en recerca clínica. Entra per saber quins assaigs clínics estem duent a terme i perquè som referent mundial en aquest camp.
Progrés
Volem que la recerca que es fa al Vall d’Hebron Institut de Recerca (VHIR) sigui un motor de transformació. Com? Identificant noves vies i solucions per fomentar la salut i el benestar de les persones.
Core facilities
Oferim un suport especialitzat als investigadors tant interns com externs, des d’un servei concret fins a l’elaboració d’un projecte complet. Tot, amb una perspectiva de qualitat i agilitat de resposta.
Actualitat
Et donem una porta d’entrada per estar al dia de tot el que passa al Vall d’Hebron Institut de Recerca (VHIR), des de les últimes notícies fins a les activitats i iniciatives solidàries futures que estem organitzant.
Speaker; Dr. Diana Rafael, main researcher Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) VHIR
Abstract: The constant development of new synthetic drug delivery systems in the last years have been highly contributing to the advancement of new treatments for a wide-range of challenging diseases, for which the conventional treatments are not efficient. The use of nanoparticles and hydrogels have been a breakthrough in clinical application, with hundreds of new products enrolling clinical trials and being approved in the clinical practice. In the CB-DDT group we are experts in the development of new therapeutic strategies based on nanoparticles and hydrogels for several different clinical applications. This presentation will be divided in two parts: The first one dedicated to the most promising works regarding the development of nanoparticles encapsulating different drugs and biomolecules for the systemic treatment of different pathological conditions, and the second one dedicated to the most promising results regarding the use of biodegradable, smart hydrogels for cancer local treatment.
Bio Sketch: Diana Rafael, is a Principal Investigator at VHIR. She has a PhD in Pharmaceutical Technology (2017), and since 2013 she has been associated with the Clinical Biochemistry: Drug Delivery and Therapy Group from VHIR, where she initiated a research line dedicated to the production and characterization of Delivery Systems. Diana participated in more than 12 highly competitive national and international research projects and her research work originated 2 patents and more than 40 peer-reviewed publications. This year, Diana was granted with a Global Marie Sk³odowska-Curie Postdoctoral Fellowship and a Grant from the Spanish Association against the Pancreatic Cancer. Moreover, since January Diana has been implementing a new section within the FVPR/U20 platform of the Nanbiosis, certified by ISO9001:2015, dedicated to the synthesis and characterization of Nanosystems.
Host: Dr. Ibane Abasolo, head of group Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) VHIR
